Based in Mountain View, California, Charter Life Sciences focuses on investing in early-stage opportunities in the biotechnology, drug development, medical device, and healthcare information technology sectors. They prefer to invest in companies that are in the clinical stage and have a focus on biologic and small molecule opportunities, therapeutic devices and diagnostics, and information access needs in healthcare. Charter Life Sciences typically invests in Series A or Series B rounds, with initial investments ranging from $1 million to $5 million. They have a track record of successful investments in companies such as APT Pharmaceuticals, CoMentis, and WhiteLight Systems, and have exited investments in CymaBay Therapeutics and Bullhorn, among others.